XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Cash flows used in operating activities:              
Net loss $ (2,800) $ (2,720) $ (1,839) $ (1,087) $ (5,520) $ (2,926)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         179 188  
Amortization of deferred financing costs and debt discount         283 275  
In process research and development acquired from NanoTx Therapeutics         0 781  
Noncash lease expenses         4 9  
Change in fair value of warrants     (756)   (2) (2,423)  
Stock-based compensation expense         245 55  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Accounts receivable         0 218  
Other current assets         (11) 487  
Other assets         0 54  
Accounts payable and accrued expenses         (583) 371  
Net cash used in operating activities         (5,405) (2,911)  
Cash flows used in investing activities:              
Purchases of property and equipment         (80) (23)  
In process research and development acquired from NanoTx Therapeutics         0 (400)  
Net cash used in investing activities         (80) (423)  
Cash flows provided by (used in) financing activities:              
Principal payments of long-term obligations         0 (5,307)  
Payment of financing lease liability (3)   (33)   (8) (51)  
Proceeds from exercise of warrants         2,017 366  
Proceeds from sale of common stock, net         12,291 0  
Net cash provided by (used in) financing activities         14,300 (4,992)  
Net increase (decrease) in cash and cash equivalents         8,815 (8,326)  
Cash and cash equivalents at beginning of period   $ 8,346   $ 17,592 8,346 17,592 $ 17,592
Cash and cash equivalents at end of period $ 17,161   $ 9,266   17,161 9,266 $ 8,346
Cash paid during period for:              
Interest         290 372  
Supplemental schedule of non-cash investing and financing activities:              
Common stock issued in payment for in process research and development         0 381  
Unpaid offering cost         119 0  
Right-of-use asset obtained in exchange for lease liabilities         $ 81 $ 0